JP2017500334A5 - - Google Patents

Download PDF

Info

Publication number
JP2017500334A5
JP2017500334A5 JP2016541280A JP2016541280A JP2017500334A5 JP 2017500334 A5 JP2017500334 A5 JP 2017500334A5 JP 2016541280 A JP2016541280 A JP 2016541280A JP 2016541280 A JP2016541280 A JP 2016541280A JP 2017500334 A5 JP2017500334 A5 JP 2017500334A5
Authority
JP
Japan
Prior art keywords
alkyl
aliphatic
independently
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017500334A (ja
JP6883988B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071644 external-priority patent/WO2015095783A1/en
Publication of JP2017500334A publication Critical patent/JP2017500334A/ja
Publication of JP2017500334A5 publication Critical patent/JP2017500334A5/ja
Application granted granted Critical
Publication of JP6883988B2 publication Critical patent/JP6883988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541280A 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 Active JP6883988B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361919394P 2013-12-20 2013-12-20
US201361919390P 2013-12-20 2013-12-20
US61/919,390 2013-12-20
US61/919,394 2013-12-20
US201462075743P 2014-11-05 2014-11-05
US62/075,743 2014-11-05
PCT/US2014/071644 WO2015095783A1 (en) 2013-12-20 2014-12-19 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019193538A Division JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Division JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Publications (3)

Publication Number Publication Date
JP2017500334A JP2017500334A (ja) 2017-01-05
JP2017500334A5 true JP2017500334A5 (enExample) 2018-02-01
JP6883988B2 JP6883988B2 (ja) 2021-06-09

Family

ID=53403769

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016541280A Active JP6883988B2 (ja) 2013-12-20 2014-12-19 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2019193538A Pending JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019193538A Pending JP2020011998A (ja) 2013-12-20 2019-10-24 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
JP2021031721A Withdrawn JP2021080287A (ja) 2013-12-20 2021-03-01 ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法

Country Status (11)

Country Link
US (2) US10329301B2 (enExample)
EP (2) EP4032889B1 (enExample)
JP (3) JP6883988B2 (enExample)
CN (2) CN112409363B (enExample)
AU (1) AU2014368961B2 (enExample)
CA (2) CA3123897C (enExample)
IL (1) IL246261B (enExample)
MX (2) MX381561B (enExample)
NZ (2) NZ722077A (enExample)
WO (1) WO2015095783A1 (enExample)
ZA (1) ZA201605027B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3310785B1 (en) * 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US10449181B2 (en) 2016-08-25 2019-10-22 Sarah E. Labance Treatment of autism and autism spectrum disorders (ASD)
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12636291B2 (en) 2019-02-13 2026-05-26 Centre For Addiction And Mental Health Compositions and methods relating to use of agonists of ALPHA5-containing GABAA receptors
JP2022534704A (ja) 2019-06-04 2022-08-03 ヘイガー バイオサイエンシズ,エルエルシー オレキシンアンタゴニストとしてのイミダゾロ誘導体、組成物、及び方法
IL294031A (en) * 2019-12-19 2022-08-01 Agenebio Inc History of benzodiazepines, preparations and methods for the treatment of cognitive impairment
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
US12649738B2 (en) 2020-03-26 2026-06-09 Richter Gedeon Nyrt. 1,3-dihydro-2H-pyrrolo[3,4-c]pyridine derivatives as GABAA α5 receptor modulators
EP4178961A4 (en) * 2020-07-10 2024-07-31 Agenebio, Inc. POLYMORPHS OF A GABAA APLHA5 AGONIST AND METHODS OF USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT
JP7867287B2 (ja) * 2020-07-10 2026-05-29 エージンバイオ, インコーポレイテッド Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法
CN113284553B (zh) * 2021-05-28 2023-01-10 南昌大学 一种用于治疗药物成瘾的药物靶点结合能力测试方法
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
EP4572852A1 (en) 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
US20250375429A1 (en) 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3391142A (en) 1966-02-09 1968-07-02 Lilly Co Eli Adamantyl secondary amines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
NL7305644A (enExample) 1972-04-20 1973-10-23
NL7605526A (nl) 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4816456A (en) 1986-10-01 1989-03-28 Summers William K Administration of monoamine acridines in cholinergic neuronal deficit states
NL195004C (nl) 1987-03-04 2003-11-04 Novartis Ag Fenylcarbamaat bevattend farmaceutisch preparaat.
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
CA2000786C (en) 1988-11-07 1999-01-26 Janssen Pharmaceutica, Naamloze Vennootschap 3-piperidinyl-1,2-benzisoxazoles
US5043345A (en) 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DE10299048I2 (de) 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
ES2076253T3 (es) 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
JP2807577B2 (ja) 1990-06-15 1998-10-08 エーザイ株式会社 環状アミド誘導体
JP2800953B2 (ja) 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
ATE180475T1 (de) * 1990-09-21 1999-06-15 Rohm & Haas Dihydropyridazinone und pyridazinone als fungizide
US5190951A (en) 1990-10-19 1993-03-02 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
WO1992020682A1 (en) * 1991-05-24 1992-11-26 E.I. Du Pont De Nemours And Company Arthropodicidal anilides
US5106856A (en) 1991-06-07 1992-04-21 Hoechst-Roussel Pharmaceuticals Inc. [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
TW201311B (enExample) * 1991-06-17 1993-03-01 Hoffmann La Roche
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
ATE167057T1 (de) 1994-03-02 1998-06-15 Akzo Nobel Nv Sublinguales oder bukkales arzneimittel
US6479523B1 (en) 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
WO1999025353A1 (en) 1997-11-13 1999-05-27 Merck Sharp & Dohme Limited Therapeutic uses of triazolo-pyridazine derivatives
US6294583B1 (en) 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
CA2349700A1 (en) 1998-11-12 2000-05-18 Merck & Co., Inc. Therapeutic polymorphs of a gaba-a alpha-5 inverse agonist and pamoate formulations of the same
US6677330B1 (en) 1999-03-03 2004-01-13 Eisai Co., Ltd. Fluorides of 4-substituted piperidine derivatives
GB9911803D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911804D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9911802D0 (en) 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
GB9929569D0 (en) 1999-12-14 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US20020151591A1 (en) 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
TWI239333B (en) * 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
IL157465A0 (en) 2001-03-01 2004-03-28 Pfizer Products Inc Pfizer Pro Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
US6686352B2 (en) * 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
WO2003025122A2 (en) 2001-08-13 2003-03-27 University Of Kentucky Research Foundation Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment
CA2473536A1 (en) 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
CA2495285A1 (en) 2002-08-13 2004-02-19 Merck Sharp & Dohme Limited Phenylpyridazine derivatives as ligands for gaba receptors
GB0218876D0 (en) 2002-08-13 2002-09-25 Merck Sharp & Dohme Therapeutic agents
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
CN100339070C (zh) 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
MXPA05005398A (es) 2002-11-22 2006-03-09 Univ Johns Hopkins Meta para terapia de deterioro cognitivo.
AU2004316119B2 (en) 2003-10-22 2008-04-24 Merz Pharma Gmbh & Co. Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic AB peptides in amyloidopathies
US20060079582A1 (en) 2004-09-23 2006-04-13 Jeffrey Jonas Memantine for the treatment of childhood behavioral disorders
ATE402707T1 (de) 2004-10-12 2008-08-15 Hoffmann La Roche Imidazoä1,5aütriazoloä1,5dübenzodiazepin- derivative zur behandlung kognitiver störungen
NZ554439A (en) 2004-10-20 2009-09-25 Hoffmann La Roche Imidazo-benzodiazepine derivatives
RU2007114763A (ru) * 2004-10-20 2008-11-27 Ф.Хоффманн-Ля Рош Аг (Ch) Галогенозамещенные производные бензодиазепинов
WO2006063708A1 (en) * 2004-12-14 2006-06-22 F.Hoffmann-La Roche Ag Tetracyclic imidazo-benzodiazepines as gaba receptors modulators
US20060205822A1 (en) 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US7595395B2 (en) 2005-05-16 2009-09-29 Wisys Technology Foundation Gabaergic agents to treat memory deficits
EP1924712B1 (en) 2005-08-03 2018-10-03 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
JP4885967B2 (ja) * 2005-10-11 2012-02-29 エフ.ホフマン−ラ ロシュ アーゲー イミダゾベンゾジアゼピン誘導体
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
WO2010014220A1 (en) 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
WO2010036553A1 (en) 2008-09-24 2010-04-01 E. I. Du Pont De Nemours And Company Fungicidal pyridazines
BRPI0920515B1 (pt) 2008-09-25 2018-03-20 Vive Nano, Inc. Composição compreendendo nanopartícula de polímero e composto ativo agrícola
EP2419401A2 (en) 2009-04-17 2012-02-22 XenoPort, Inc. GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS
WO2011085406A1 (en) 2010-01-11 2011-07-14 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
CN103189062B (zh) * 2010-11-05 2016-03-23 霍夫曼-拉罗奇有限公司 活性药物化合物用于治疗中枢神经系统病症的用途
MX2013005443A (es) * 2010-11-15 2013-10-07 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
AU2011328993B2 (en) 2010-11-15 2017-03-02 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
JPWO2012161133A1 (ja) 2011-05-20 2014-07-31 日産化学工業株式会社 置換ピリダジン化合物及び農園芸用殺菌剤
US20150374705A1 (en) * 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
WO2014039920A1 (en) 2012-09-10 2014-03-13 Lewin Matthew R Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade
EP4032889B1 (en) 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN108567787A (zh) 2017-03-10 2018-09-25 辛衍雪 一种治疗慢性阻塞性肺病的药物组合物
AU2019288382B2 (en) 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Similar Documents

Publication Publication Date Title
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2021528427A5 (enExample)
JP2018521034A5 (enExample)
JP6466348B2 (ja) スルファモイル−アリールアミドおよびb型肝炎を処置するための医薬品としてのその使用
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
JP2019034943A5 (enExample)
JP2019519598A5 (enExample)
JP2020528889A5 (enExample)
JP2014503574A5 (enExample)
JP2019518071A5 (enExample)
JP2019518766A5 (enExample)
JP2019515952A5 (enExample)
JP2018507877A5 (enExample)
JP2013544846A5 (enExample)
JP2017518959A5 (enExample)
JP2013542267A5 (enExample)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
JP2011500621A5 (enExample)
JP2012532112A5 (enExample)
EA023824B1 (ru) ПРОИЗВОДНЫЕ 3,4-ДИГИДРОПИРРОЛО[1,2-a]ПИРАЗИН-1-ИЛАМИНА, ПРИГОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ БЕТА-СЕКРЕТАЗЫ (BACE)
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017176962A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP2020512389A5 (enExample)
PE20220964A1 (es) Derivados de n-metil, n-(6-(metoxi)piridazin-3-il) amina como moduladores de autotaxina (atx) para el tratamiento de enfermedades inflamatorias de las vias respiratorias o fibroticas
JP2017508733A5 (enExample)